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A recent proposal is that the alpha
1
-adrenoceptor may mediate the 
arrhythmogenic effect of catecholamines during acute myocardial 
ischaernia. The purpose of this thesis was to explore the role of alpha
1 
and alpha2-adrenoceptor stimulation on vulnerability to ventricular 
fibrillation in the norrnoxic rat ventricular myocardium and further to 
evaluate the possible underlying cellular mechanism. 
The model used was the isolated perfused rat heart (Langendorff 
technique) in which ventricular fibrillation was electrically induced. 
The amount of current required to produce ventricular fibrillation was 




increased the vulnerability 
with methoxamine to 
to ventricular fibrillation. The 
arrhythmogenic effect of methoxamine could not be attributed to 
beta-adrenoceptor stimulation as it occurred in the setting of the 
beta-adrenocepto r antagonist agent, atenolol; furthermore no 
accumulation of cyclic AMP, the proposed arrhythmogenic second messenger 
of beta-adrenoceptor stimulation, occurred. Similarly no alteration in 
heart rate, coronary flow rate or myocardial high energy phosphate 
content accompanied the arrhythrnogenic effect of methoxarnine. The QT 
interval increased with alpha
1
-adrenoceptor stimulation, this being an 
indirect index of prolongation of the action potential duration. The 
arrhythmogenic action of methoxamine was associated with a positive 
inotropic effect. 
(x) 
Prazosin 10-BM (an alpha
1-adrenoceptor antagonist agent) produced a 
tenfold displacement to the right of the log concentration response 
curve of the positive inotropic effect of methoxamine. -8 Prazosin 10 M 
prevented the methoxamine induced fall in ventricular fibrillation 
threshold. Alpha
2
-adrenoceptor stimulation with B-HT 920 and B-HT 933 
(azepexole), in the presence of the beta-adrenoceptor antagonist agent 
atenolol , did not alter the vulnerability to ventricular fibrillation. 
Alpha
2
-adrenoceptor stimulation produced no alteration in heart rate, 
coronary flow rate or metabolic status. 
We next explored the possible mechanism underlying the arrhythmogenic 
effect of methoxamine . Alpha 1-adrenoceptor stimulation enhances 
transsarcolemmal calcium ion influx and may induce sarcoplasmic 
reticulum calcium release . To assess the role of transsarcolemmal 
calcium movement in alp~a
1
-adrenoceptor mediated effects experiments 
were undertaken with nisoldipine and low extracellular calcium. To 
evaluate the role of sarcoplasmic reticulum calcium release, experiments 
were undertaken with ryanodine (an agent reputed to inhibit sarcoplasmic 
reticulum calcium release without effecting the slow inward current). 
Nisoldipine l0-
8
M, reducing extracellular calcium (2.5 mM to 1.25 mM) 
-9 -8 and ryanodine 10 M to 10 M, prevented the arrhythmogenic and positive 
inotropic effect of methoxamine. Heart rate, metabolic status and 
cyclic AMP levels we're unchanged with these procedures. 
The mechanism underlying the arrhythmogenic action of 
alpha
1
-adrenoceptor stimulation might be an increase in cytosolic 
calcium concentration. This increase may be secondary to (i) an 
enhanced transsarcolemmal calcium influx or (ii) an increase in the 
phasic release of calcium from the sarcoplasmic reticulum. 
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INTRODUCTION 
The incidence of acute myocardial infarction and complications of 
cardiac morbidity and mortality in South Africa is reputed to be the 
highest in the world (360 deaths per 100,000 population in 1979). In 
the United Kingdom the Edinburgh community study shows that fifty 
percent of all deaths following acute myocardial infarction occur 
within two hours, the majority of which are sudden (Armstrong et al., 
1972). Current experimental evidence suggests that ventricular 
fibrillation is the mechanism underlying sudden death. To reduce the 
high mortality rate following acute myocardial infarction requires the 
prevention of this early ventricular fibrillation; implicit in this 
concept is understanding the pathogenesis of ventricular fibrillation. 
A) Catecholamines and ventricular fibrillation 
Several lines of evidence indicate that enhanced adrenergic 
activity plays an important role in the genesis of ventricular 
fibrillation. Elevated plasma and urinary catecholamine levels 
follow myocardial infarction (Wollenberger and Shahab, 1965. 
Gauduel et al., 1979); circulating catecholamines facilitate the 
development of ventricular arrhythmias. Surgical denervation of 
the heart significantly reduces the incidence of ventricular 
fibrillation following coronary occlusion (Ebert et al., 1970). 
Similarly chemical denervation of the heart with 
6-hydroxydopamine or reserpine protects against the development 
of ventricular fibrillation during both coronary occlusion and 
reperfusion (Sethi et al., 1973; Sheridan et al., 1980; Sommers 
and Jennings, 1972). These findings suggest that sympathetic 
stimulation is an important factor contributing to the genesis of 
B) 
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ventricular fibrillation during acute myocardial infarction. 
Enhanced adrenergic activity results in stimulation of both the 
alpha- and beta-adrenergic receptors. 
The beta-adrenoceptor and ventricular fibrillation 
It has generally been considered that the arrhythmogenic effect 
of catecholamines during acute myocardial ischaemia is mediated 
by beta-adrenoceptor stimulation (Lubbe et al., 1978). Cyclic 
AMP, the proposed intracellular second messenger of beta-receptor 
stimulation, has been linked to the genesis of ventricular 
fibrillation. 
Evidence for this hypothesis is as follows:-
1) Elevated cyclic AMP levels have been demonstrated in the 
ischaemic myocardium of baboon heart prior to the onset 
of ventricular . fibrillation (Podzuweit et al., 1978). 
2) In the pig a relationship exists between post-ligation 
ventricular arrhythmias and the accumulation of myocardial 
cyclic AMP (Podzuweit and Lubbe, 1977). 
3) In cats with regional myocardial ischaemia, ventricular 
arrhythmias are accompanied by increased myocardial cyclic 
AMP levels (Corr et al., 1978). 
4) The dose-response curve linking increases in tissue cyclic 
AMP with the decrease in the ventricular fibrillation 
threshold in the isolated rat heart model (Lubbe et al., 
1976, 1978). 
5) The shift of the dose-response curve to the right and the 
delay in the rise of tissue cyclic AMP during 
beta
1
-adrenergic antagonism with atenolol, (Lubbe et al, 
1978). 
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C) Possible electrophysiological alterations induced by cyclic AMP. 
D) 
Cyclic AMP increases transsarcolemrnal calcium influx by 
phosphorylation of the slow channel (Reuter 1974), this may induce 
ventricular arrhythmias by the following electrophysiological 
mechanisms, 
1. Enhanced sarcolemrnal calcium conductance may induce slow 
response action potentials in partially depolarized muscle 
fibres (Reuter, 1974), this predisposes to slow conduction and 
unidirectional conduction block thereby satisfying the 
requisites for the occurrence of re-entry. 
2. Intracellular calcium ion overload may evoke delayed after 
depolarizations and thereby induce triggered automaticity. 
3. Intracellular calcium ion overload may increase internal 
longitudinal res~stance, ~ause uncoupling of cells and lead to 
ventricular fibrillation. 
Effect of beta-adrenoceptor antagonist agents on ventricular 
fibrillation during acute myocardial ischaemia 
· 1) In the dog beta-receptor antagonist agents, in general, 
prevent spontaneous ventricular fibrillation (Khan et al., 
1972) and also inhibit the fall in ventricular fibrillation 
threshold. (Anderson et al, 1983). 
2) In the rat (Thandroyen et al., 1983) and cat, (Sheridan et 
al., 1980) beta-receptor antagonists, in concentrations 
producing beta-receptor antagonism, do not prevent 




than that required to achieve beta-receptor antagonism some 
beta-antagonists prevent ventricular fibrillation (Thandroyen 
et al., 1983) possibly by a non specific method eg membrane 
stabilization action. (Barrett and Cullum, 1968). 
Clinical efficacy of beta-adrenoceptor antagonist agents 
The "beta-blocker heart attack clinical trials" tested whether 
regular administration of propranolol, (American beta-blocker 
heart attack trial research group, 1982) timolol (The Norwegian 
multicentre study group, 1981) and metoprolol (Herlitz et al, 
1983) within 3 hours to 5 days of the onset of acute myocardial 
infarction, would result in a significant reduction in sudden 
death and cardiac mortality. All three trials showed a decrease 
in total cardiac mortality and sudden death: after 3 months in 
the metoprolol tr~al, 17 months in the timolol trial and 27 
months in the propranolol trial. This suggests that long term 
treatment with beta-antagonist agents in patients surviving acute 
myocardial infarction reduces mortality. None of these clinical 
trials assess the effect of administration of beta-adrenoceptor 
antagonist agents within sixty minutes of the onset of acute 
myocardial infarction. 
The alpha-adrenoceptor and ventricular fibrillation 
A recent hypothesis is that the alpha1-adrenoceptor may mediate 
the arrhythmogenic effect of catecholamines during acute 




-adrenergic receptor number, as assessed by ligand 
binding with (3H) prazosin, increased nearly two-fold in 
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ischaemic cat myocardium within thirty minutes of coronary 
occlusion; a temporal association was evident with 
ventricular arrhythmias. (Corr et al., 1981). Receptor 
affinity (Kd) was not altered at any interval studied. The 
mechanism responsible for the increase in alpha
1-receptor 
number during ischaemia is not known; it has been postulated 
that alterations in membrane phospholipids in ischaemic 
tissue may influence the relative number of adrenergic 
receptors (Sobel et al., 1978). 
2) Enhanced alpha-adrenergic responsiveness during reperfusion 
was demonstrated with the alpha
1-agonist methoxamine (Corr et 
al., 1981). 
3) Prazosin, a sp~cific al~ha
1
-adrenoceptor antagonist agent 
reduced premature ventricular complexes and ventricular 
fibrillation in the feline (Sheridan et al., 1980) and rat 
model (Thandroyen et al., 1983) of coronary artery 
ligation. 





-adrenoceptor antagonist agents prevented ventricular 
fibrillation during acute myocardial ischaemia. (Thandroyen 
et al., 1983). 
Enhanced alpha-adrenergic responsiveness which occurs during 
acute myocardial ischaemia has been temporally related to 
the occurrence of ventricular arrhythmias. However the 










1) Delayed after-depolarizations (Vassalle and Musso, 1976). 
2) Slow response type depolarizations (Miura et al., 1978). 
3) Enhanced automaticity (Penkoske et al., 1978). 
4) Increased idioventricular rate (Penkoske et al., 1978). 
Clinical efficacy of alpha 1-adrenoceptor antagonist agents 
The effect of specific alpha1-adrenoceptor antagonist agents on 
sudden death and cardiac mortality has not been investigated 
during acute myocardial infarction in man. However Gould and 
coworkers in 1975 showed that the non specific alpha-adrenoceptor 
antagonist phentolamine did reduce the incidence of late onset 
ventricular premat_ure beats· during acute myocardial infarction 
(Gould et al., 1975). 
Classification of alpha-adrenoceptors 
Williams and Lefkowitz (1978) were the first to document the 
presence of myocardial alpha-adrenoceptors using radioligand 
binding techniques. Further experimentation with this technique 
suggested that two subtypes of alpha-adrenoceptors exist, these 
being distinguished on the basis of differential affinities of 
certain adrenergic ligands for each receptor subtype (Yamada et 
al., 1980. Williams et al., 1980). The two subtypes of 
alpha-adrenoceptors proposed were termed pre and postsynaptic 
receptors, the presynaptic alpha-adrenoceptor being l _ocated at 
1-7 
the level of the membranes of vesicles (storage sites of 
endogenous neurotransmitters). Excitation of the presynaptic 
alpha-adrenoceptor was postulated to inhibit the release of 
endogenous noradrenaline from the vesicles and to act as an 
inhibitory feedback mechanism. Stimulation of the postsynaptic 
alpha-adrenoceptor was postulated to mediate smooth muscle 
contraction (Van Zwieten and Timmermans., 1983). 










However it was 
subsequently demonstrated that the preference for appropriate and 
selective agonists and antagonists of alpha-adrenoceptors did not 
run parallel to the pre- and post location of the receptors (Van 
Zwieten and Timmenpans., 1983). Postsynaptic alpha2-adrenoceptors 
exist which induce vasoconstriction in vivo (Van Meel et al., 
1981). 
More recent nomenclature classifies the alpha-adrenoceptor 
subtypes as follows: 
(a) the terms pre- and postsynaptic refer solely to the anatomical 





indicates the preference of the receptors for 
certain agonists and antagonists, this preference is not 
necessarily associated with a defined anatomical position of the 
receptor (Table 1). 
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Table 1 
































Alpha-a<lrenoceptors in the rat heart 
Williams and co-workers investigated the binding characteristics 
3 of a ligand relatively selective to the alpha2-adrenoceptor, ( H) 
clonidine, as well as one selective to the alpha1-adrenoceptor, 
( 3H) Prazosin, in rat heart homogenates. 
K) 
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The relatively selective alpha
2
-ligand (3H) clonidine, at 
concentrations up to 20 nM, demonstrated negligible binding 
whereas the alpha1-specific ligand (
3H) prazosin saturated 
the binding sites. (Williams et al., 1980). These findings 
suggest that the alpha-adrenoceptors in the rat heart are 
predominantly of the alpha
1
-subtype. Glossmann (Glossmann et 
al., 1980) also indentified only alpha
1
-adrenoceptors in the 
rat myocardium. 
Only one study provides evidence for the presence of 
alpha
2
-adrenoceptor subtypes in the rat heart (Guicheney and 
Meyer, 1981). Thus alpha-adrenoceptors in the rat 




i) Cyclic nucleotides (cAMP and cGMP) 
Unlike beta-adrenoceptor stimulation, alpha-adrenoceptor 
stimulation is not associated with the accumulation of 
intracellular cyclic AMP. Methoxamine, the 
alpha
1
-adrenoceptor agonist agent has been reported to exert 
a positive inotropic effect with no increase in myocardial 
cyclic AMP content (Endoh et al., 197 5. Schumann et al., 
1975). In another study methoxamine has been reported to 
decrease cyclic AMP levels independently of adenylate 
cyclase whereas alpha2-adrenoceptor stimulation decreases 
cyclic AMP levels through the inhibition of adenylate 
cyclase (Schumann et al., 1975. Exton 1983. Hoffman et al., 
1980. Tsai et al., 1979.). These studies imply that 
alpha-adrenergic responses occur independently of cyclic AMP 
accumulation. 
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A transient increase in cyclic GMP has been reported to 
follow alpha-adrenoceptor stimulation in several studies 
(Goldberg and Haddox, 1977. Amer and Byrne, 1975. Kunos et 
al., 1976. Watanabe and Besch, 1975). Other workers report 
no change in cyclic GMP concentration following 
alpha-adrenoceptor stimulation (Gardner and Allen, 1976, 
1977). A change in cyclic GMP content does not appear to be 
a prerequisite for alpha-adrenoceptor mediated responses. 
(ii) Calcium 








by stimulating vascular 
postsynaptic alpha
2
-adrenoceptors can be reduced by use of 
calcium channel blocking agents through a non-competitive 
mechanism. Vasoconstriction evoked by stimulating vascular 
alpha
1
-adrenoceptors are not influenced by calcium channel 
blocking agents (Van Zwieten et al., 1983). These findings 
suggest that alpha
2
-adrenoceptor stimulation increases, 
whereas alpha
1
-adrenoceptor does not effect, the inward 
calcium current in vasculature. Similar findings have been 
reported by Van Meel et al., 1980 and Muiro et al., 1978. 
I 
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(b) Liv er 
Alpha
1
-adrenoceptor stimulation may induce depolarization and the 
release of calcium ions from intracellular stores (Ex ton, 1981). 
In the adult rat liver, alpha1-adrenoceptor responses are 
mediated by a calcium sensitive cascade triggered by a transient 
rise in cytosolic calcium (Ex ton, 1981). 
(c) Heart 
L) 
Alpha1-adrenoceptor stimulation increases the slow inward current 
in ventricular muscle (Scholz, 1980). In a preliminary 
communication alpha1-adrenoceptor stimulation has been 
demonstrated to phosphorylate a 15,000 MW protein localized to 
the sarcolemma, this possibly being the slow inward current 
regulatory mechanism (Lindemann and Wilson, 1984). 
Alpha
1 
-adrenocepto~ stimulation does not phosphorylate the 
sarcoplasmic reticulum protein phospholamban. As in the liver, 
alpha
1
-adrenoceptor stimulation may induce sarcoplasmic reticulum 
calcium release. Although very little is known about the 
mechanisms involved in alpha-adrenoceptor responses, available 
evidence strongly indicates that calcium may play a role as 
mediator. 
Myocardial alpha-adrenoceptor responses 
(i) Heart rate 
Both positive and negative chronotropic changes 
have been reported following alpha-adrenoceptor stimulation 
(James et al., 1968, Rosen et al., 1977). 
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The sinus node does not respond to alpha-adrenoceptor 
stimulation, similarly no e f fect occurs on the pacemaker 






(ii) Left Ventricular Pressure 
Hauswirth et 





An alpha 1-adrenoceptor mediated positi
ve inotropic effect has 
been observed in isolated heart preparations of rat, cat, guinea 
pig and also of man (Schilmann et al., 1978. Endoh and Schilmann, 
1975a. Ledda et al., 1975. Mugelli et al., 1976). 
Phenylephrine, an alpha
1
-agonist agent, induces a positive 
inotropic response in the rat model (these experiments were 
c onducted in the presence of propranolol, a beta-antagonist 




antagonist agent) antagonises the inotropic response of 
pheny lephrine (Osnes et al., 1975). The positive inotropic 
profile of alpha-adrenoceptor stimulation differs from that of 
beta-adrenoceptor stimulation in the following aspects: Firstly 
there is no shortening of the time to peak tension. Secondly, 
the peak inotropic response is reached later (i.e. 240 seconds as 
opposed to 15 to 30 seconds). Thirdly, relaxation is not altered 
(Skomedal et al., 1977). 
These qualitative differences between alpha and beta-adrenoceptor 
stimulation indicate the involvement of two different mechanisms 
of action. The mechanism underlying the alpha-adrenoceptor 
(iii) 
1-13 
mediated positive inotropic response is unknown; cAMP and 
sodium/potassium ATPase activity remain unchanged (Scholz, 
1980. Endoh et al., 1975). It has been postulated that 
alpha-adrenoceptor effects may be mediated by increasing 




-adrenoceptor stimulation with methoxamine 
induces coronary artery vasoconstriction in the rat model 
(Glomstein et al ., 1967). In the presence of 
beta-adrenoceptor antagonism, coronary artery 
vasoconstriction follows sympathetic nerve activation. This 
vasoconstriction is prevented by alpha-adrenoceptor 
antagonist ag~nts (Adam et al., 1970. Ek and Ablad, 1971, 
Feigl , 1975. Hamilton and Feigl, 1976). 
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HYPOTHESIS 
The hypothesis addressed is that alpha-adrenoceptor mediated responses 
play a role in the genesis of ventricular fibrillation. The 
arrhythmogenic potential of alpha
1 
and alpha2-adrenoceptor stimulation 
in normoxic ventricular myocardium is undefined as is the possible 
underlying cellular mechanism. 





stimulation on (1) vulnerability to ventricular fibrillation in the 
isolated perfused normoxic rat heart. 
(2) coronary perfusion, mechanical function and 
myocardial metabolic status. 
(3) transsarcolemmal calcium ion movement and 
sarcoplasmic reticulum calcium ion release. 
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CHAPTER 2 
MODEL, MATERIALS AND METHODS 
1) EXPERIMENTAL MODEL 
A) Isolated perfused rat heart 
B) 
The isolated Langendorff perfused rat heart was chosen as the 
model to investigate the role of alpha-adrenergic receptor 
stimulation on vulnerability to ventricular fibrillation . 
Advantages of Model 
1) In the intact in vivo animal model alpha1-
adrenoceptor stimulation 
causes peripheral vasoconstriction and a reflex bradycardia. The 
direct influence of alpha1-adrenoce
ptor stimulation on the 
myocardium is therefore not able to be analysed. The isolated 
perfused heart preparation is independent of peripheral 
circulation, neuronal and hormonal influence. Hence analysis may 
be undertaken of the direct action of alpha-adrenoceptor 
stimulation on the ventricular myocardium. 
2) Specific concentrations of alpha-adrenoceptor agonists and 
antagonists can be delivered to the myocardium by adding these 




adrenoceptor agonists/antagonists on 
vulnerability to ventricular fibrillation can be accurately 
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evaluated. 
3) Metabolic and biochemical analysis can be measured and related to 
the effects of alpha-adrenoceptor stimulation/antagonism. 
4) The arrhythmogenic action of alpha-adrenoceptor stimulation may be 
due to an increase in myocardial cell calcium concentration 
following cell membrane receptor stimulation . The role of calcium 
ions can be addressed by alteration of calcium ion concentration 
in the perfusate. 
5) The arrhythmogenic action of alpha-adrenoceptor stimulation may be 
mediated by coronary vascular constriction causing focal 
myocardial ischaemia. This model enables one to accurately record 
coronary flow rateq and henc~ relate alteration in coronary 
perfusion to vulnerability to ventricular fibrillation. 
6) Catecholamine stimulation per se does not induce spontaneous 
ventricular tachycardia/ventricular fibrillation in the normoxic 
heart . The advantage of electrically induced ventricular 
fibrillation is that small changes in vulnerability to ventricular 
fibrillation can be measured. 
7) Ventricular fibrillation induced by electrical current usually 
spontaneously reverts to sinus rhythm. Repeated measurements of 
ventricular fibrillation threshold can therefore be done on the 
same heart . 
8) Conversion of ventricular fibrillation to sinus rhythm can be 
achieved by simple immersion of the heart in ice-cold Krebs-
Henseleit buffer, this procedure causes minimal damage and is 
effective. 
9) The model is not costly and rats are easily available. 
C) Disadvantages of the Model 
2-3 
1) The perfusion fluid has no haemoglobin, hence coronary flow rates 
are unduly high. 
2) Absence of autonomic neuronal innervation. 
3) Due to the aortic retrograde perfusion, no volume work is 
performed by the heart. 
4) No peripheral circulation exists . 
. 5) Artificial induction of ventricular fibrillation (see below). 
D) Ventricular Fibrillation Threshold 
The artificial induction of ventricular fibrillation by delivery 





synonymous with spontaneous ventricular fibrillation. Hence the 
changes in vulnerability to ventricular fibrillation evoked by 
this technique cannot be extrapolated to alterations in 
spontaneous ventricular fibrillation. 
Wiggers and co-workers (1940) proposed that vulnerability to 
ventricular fibrillation is a specific and inherent property of 
the myocardium, Dawes (1952) however, considered it to represent 
a measurement of myocardial excitability. More recently it has 
been proposed that alterations in ventricular fibrillation 
threshold may be accepted as a measure of the efficiency of an 
anti-arrhythmic agent 
Gerstenslith, 1972) . 
MATERIALS 
Animals 
(Bacaner 1968, Allen et al 1971, 
Male Long-Evans rats (240-310 g) were anaesthetised in a glass 
chamber with ether. The femoral vein was exposed by making an 
incision in the right inguinal region; 200 units of heparin was 
injected via the femoral vein . After 45 seconds the chest was 
opened via the diaphram and the heart was removed by incising the 
great vessels. The heart was immediately immersed in ice-cold 
Krebs-Henseleit solution to produce arrest. 
Langendorff Perfusion system and the Perfusate 
The incised edge of the aorta was mounted onto a metal cannula 
and perfused at 100 cm water pressure according to the 
Langendorff technique (described in 1895). The perfusion fluid 
C) 
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was Krebs-Henselei.t solution consisting of the following: NaHco3 
25.0 mM, NaCl 118.5 mM, KCl 4,75 mM, KH2Po4 1
,19 mM, MgS04 1,19 
mM and CaC1
2 
2 . 50 mM. The subs trat e was glucos e 11 mM. This 
solution was aerated with 95 % oxygen and 5% co2
. The temperature 
was maintained at 37°C throughout the system by means of a wa ter 
jacket around the glassware containing the perfusate. A Braun 
thermomix 1460 was u sed to maintain the water at a constant 
temperature. Per f usate pH ranged between 7. 35 to 7 . 40 and p0 2 
between 470 to 55 0 mmHg. Sodium and potassium levels were 
checked to be normal. 
Electrocardiogram recordings 
Continuous electrocardiograms were recorded from one electrode 
earthed on the m~tal aor tic perfusion cannula and a second 
electrode inserted superficial ly into the right ventricular 
myocardium. The electrocardiogram was visually displayed on both 
an Electronics for medicine recorder as well as a Tetronix 
storage oscilloscope. The electrocardiogram with the square wave 
indicating the trigger was continuously displayed on the 
Electronics for medicine oscilloscope . 
D) Electrical delivery system 
The electrocardiogram potent ial was amplified by an EDTA channel 
of the Electronics for Medicine Recorder . This channel has a 
tachometer and provides a synchronous output pulse . This output 
is coupled to a control box which monitors the incoming 
synchronous pulse. After manual activation this Trigger b ox 
2-6 
delivers seven pulse beats; on the seventh beat it starts the 
horizontal sweep of the storage oscilloscope (Tetronix 
oscilloscope) whilst the eighth beat activates a Grass 588 
stimulator (Grass Instrument Co ., Massachusetts). 
E) Stimulation of the left ventricle 
3. 
A) 
Two thin platinum stimulating electrodes were superficially 
inserted into the left ventricle for delivery of electrical 
current to the myocardium. The electrodes were positioned 
horizontally in parallel 10 nun apart, one at the base of the 
heart (cathode), the other at the apex (anode). Damage to the 
coronary vessels was avoided by careful positioning of the 
stimulating electrodes. 
METHODOLOGY 
Ventricular fibrillation threshold 
The train method was employed to obtain the ventricular 
fibrillation threshold. This involves the delivery of ten square 
wave pulses evenly distributed over the duration of 200 msec 
stimulation; delivery was commensed 10 msec after the trigger 
obtained from the initial pulse of the R-wave of the 
electrocardiogram. The duration of each pulse was 20 msec. 
consisting of 2 rnsec impulse and 18 msec delay between each 
pulse. 
No difference in ventricular fibrillation threshold levels were 
found comparing the train method to the single stimulus method of 
electrical stimulation - this is based on experiments conducted 
B) 
2-7 
in the ischaemic heart laboratory/University of Cape Town. 
Criteria for ventricular fibrillation 
Ventricular fibrillation was diagnosed if six or more consecutive 
ventricular complexes showed total irregularity of morphology . 
Associated with this pattern was a profound lowering of the left 
ventricular pressure with loss of the left ventricular pressure 
wave thus displaying criteria required fo r ventricular 
fibrillation, that is mechanical failure associated with 
electrical abnormality. 
The ventricular fibrillation threshold was obtained by 
stimulating the myocardium with an initial current of 3 mA, and 
progressively increasing the current in steps of 2 mA until 
ventricular fibrillation occurred. The ventricular fibrillation 
threshold was def~ned as the lowest current required to produce 
ventricular fibrillation on more than two occasions. 
In this model ventricular fibrillation usually reverts 
spontaneously to sinus rhythm. However, if ventricular 
fibrillation persisted for longer than ten seconds the hearts 
were defibrillated by immersing them in ice-cold Krebs-Henseleit 
buffer. 
Experimental protocol 
After mounting the heart a stabilization period of 15 minutes was 
allowed. The heart rate, coronary flow rate and ventricular 
fibrillation threshold were then measured in each experiment. 
2-8 
Heart rates ranged between 240-360 beats/min. Coronary flow 
rates, expressed as ml/min were measured by collecting the 
coronary effluent in a graduated measuring tube over 1 minute. 
Control values varied from 5 to 12 ml/min. Control ventricular 
fibrillation threshold values were between 5 and 14 mA. 
In those series where pharmacological agents were assessed the 
protocol was identical except that the agent was infused or 
perfused during the ten minute intervening period and thereafter 
throughout the experiment. 
4. MECHANICAL FUNCTION 
A) Methodology 
Long-Evans rat hearts were mounted onto a metal cannula as 
previously described (Langendorff technique). In this series the 
hearts were paced at a rate of 330 beats/min., this was achieved 
by inserting a pacing electrode into the right ventricular 
myocardium. The second electrode was earthed on the metal aortic 
cannula. A voltage stimulating unit was used to deliver pacing 
pulses to the right ventricle, (pulse width 0,2msec, voltage 
4-10 mA.) By pacing the hearts possible chronotropic influences 
on mechanical function were excluded. 
The anterior wall of the left atrium was excised exposing the 
mitral valve. A 1mm diameter hollow plastic cannula with a 
flattened end was introduced into the left ventricular cavity via 
2-9 
the mitral valve. The introduced end of the cannula was passed 
through the apex of the left ventricular myocardium until the 
other flattened end rested against the endocardium of the left 
ventricle. The cannula was connected to a pressure transducer 
after being flushed with normal saline to remove any air trapped 
in the system. Left ventricular diastolic and systolic pressures 
were recorded by means of a Devices recording unit (type MX216). 
Before commencement and after completion of each experiment the 
recording unit was calibrated from O to 100 mmHg using a 
baumanometer. Left ventricular systolic pressures varied from 70 
+ to 90 mmHg, mean 76.3 - 1.86 rrnnHg; end diastolic pressures varied 
+ 
from 3 to 7 mmHg, mean 4.29 - 0.23 rrnnHg. 
B) Protocol 
Afte r mounting the . heart a ~tabilization period of 15 minutes was 
allowed. The Devices recording speed for the duration of the 
experiment was 2. 5 cm/min, however to accurately record left 
ventricular pressures this speed was increased to 2. 5 cm/ sec 
during certain recording times (0,5,30,60,120,180 and 240 
seconds). Coronary flow rates were recorded intermittently 
during both the control and intervention periods. 
To assess the effects of pharmacological agents on mechanical 
function the protocol was identical except that the agent was 
infused or perfused following the 15 minute control period and 




All the chemical agents were used in the form of racemic 
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D) Statistical Methods 
E) 
+ Results are expressed as the mean - standard error of the mean 
for the number of the experiments. The number of experiments 
varied from 5 to 13 in each series. Probability (p) values were 
calculated using (a) students t test using two tailed values as 
corrected for unequal variances, and (b) analysis of variance. 
Probability values less than 0,05 indicated significant 
differences between mean values. 
Biochemical analysis 
The hearts to be biochemically analysed were freeze-clamped with 
Wollenberger clamps and freeze fried for~ 48 hours in an Edwards 
Modulyo freeze-drier. The freeze-fried hearts were then 
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homogenised in 6% percholoric acid with an Ultra-turrax 
homogeniser. The extracts were centrifuged and the supernatant 
neutralised with tris/KOH buffer to pH 7.0 and used for analysis. 
Adenosine triphosphate (ATP), phosphocreatine (PCr) were assayed 
in neutralised extracts. All compounds were 
enzymatically by spectra-photometric methods. 
assayed 
Standards, 
internal standards and blanks were included in every assay. 
1) Adenosine triphosphate (Lampbrecht and Trautschold 1974) 
The assay is based on the following reaction : 
ATP+ glucose hexokinase ADP+ G6P 
G6P + NADP G6PDH \ 6PGA + NADPH + H+ 
' 
The change in extinction at 340 nm was noted on the addition 
of hexokinase 5 pl (10 mg/ml) to O, 2 ml tissue extract, 
mixed with 2,8 ml assay medium, containing: 
MgC12 
0,10 ml; tris buffer 0,2M (pH 7,5) 1,00 ml; NADP 1% 
w/v 0,10 ml; glucose 100 mM 0,05 ml; H2
o dist 1,55 ml; 
G6PDH 1 mg/ml 0,005 ml . 
0,05 ml ADP (lOmM) is then added to provide sufficient ADP 
for subsequent assay of PCr and any further change in 
extinction is noted. 
3) 
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2) Phosphocreatine (Lampbrecht and Trautschold, 1974) 
The assay is based on the following reaction: 
PCr + ADP ___ M_g_2+ ________ _ 
Creatinine phosphokinase 
ATP+ Creatine 
The further change in extinction at 340 nm on addition of 10 
pl creatine phosphate kinase (10 mg/ml) after 30 min is 
proportional to the amount of PCr present. 
Glycogen (Good et al, 1933) 
The glycogen level was determined by the method described by 
Good et al (1931). The tissue is first digested with 40% KOH 
and heat. The glycogen in the digested tissue was 
precipitated with cold ethanol. The glycogen is hydrolysed 
to its glucose components with 2N HCl and heat (96°C) . The 
extract was then neutralised and assayed enzymatically by a 
spectrophotometric method. Standards, internal standards 
and blanks were included in every assay. The assay is based 
on the following reaction using hexokinase (HK) and glucose 
6 phosphate dehydrogenase (G6PDH). 
Glucose ATP HK \ 
\ 






The change in extinction at 340 nm was noted at the addition 
of HK and G6PDH to tissue extract and 2, 8 ml of assay 
medium. The increase in NADPH measured, is proportional to 
the amount of glucose present and thus glycogen originally 
present. 
4) Cyclic AMP 
Cyclic AMP (cAMP) was measured by the method described by 
Tovey et al (1974). This competitive protein binding assay 
is based on the following principle: 
If a stable compound A is introduced into a system which 
contains a constant amount of radioactive compound A* and is 
binding to protein P, A will displace A* from the protein 
binding sitess in propoition to its concentration. 
P + A*~ P A * (labelled complex) 
(labelled 
compound) 
P + A~ P A (unlabelled complex) 
The amount of radioactivity bound in the labelled complex 
decreases as the amount of unlabelled compound is increased. 
Cyclic AMP in the sample and a fixed quantity of tritium 
labelled cyclic AMP compete for binding to a protein with 
high specificity and affinity for cyclic AMP. The amount of 
labelled cyclic AMP - protein complex formed is inversely 
proportional to the amount of unlabelled cyclic AMP in the 
2-14 
sample. The unbound nucleotide is removed by a 
precipitation reaction using activated charcoal. A 
supernatant, containing the bound nucleotide is obtained by 
centrifugation and removed for scintillation counting. A 
standard curve is constructed . Co/Cx is plotted against 
concentration of cyclic AMP in the standard dilutions . Co: 
labelled nucleotide bound in the absence of unlabelled 
nucleotide. Cx: labelled nucleotide bound in the presence 
of a standard quantity of unlabelled nucleotide. 
Assay kit contains: Tris EDTA buffer; purified bovine 
muscle protein; (8-
3H) cyclic AMP; cyclic AMP standard; 
charcoal absorbent. (All in freeze-dried form; the 
Radiochemical Centre, Amersham, England). 
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CHAPTER 3 
THE ROLE OF ALPHA 1 AN
D ALPHA2-AD
RENOCEPTOR STIMULATION ON VULNERABILITY 
TO VENTRICULAR FIBRILLATION. 
Results 
A) Alpha1
-adrenoceptor stimulation in 
myocardium 
the normoxic ventricular 
Methoxamine acts selectively on the alpha1-ad
renoceptor (Van Meel 
et al., 1980. Kobinger and Pichler, 1980); in high concentrations 
the beta-adrenoceptor may be stimulated (Benfey 1982). To ensure a 
pure alpha-adrenoceptor mediated effect experiments were undertaken 
in the presence of the selective beta1
-adrenoceptor antagonist 
atenolol The log concentration response curve of 
-7 
methoxamine (Figure 1) demonstrates that methoxamine 10 M does not 
alter whereas methoxamine 10-
6M to 10-SM increases vulnerability to 
ventricular fibrillation; the ventricular fibrillation thresholds 
+ + 
being reduced from control values of 11.7 - 0.6 mA and 8.7 - 0.7 mA 
to 4.1 + 1.2 mA (p < 0.01) and 3.8 + 0.8 mA (p( 0.01) respectively. 
The arrhythmogenic effect of methoxamine was not accompanied by 
alteration in the following, 
(a) heart rate control values 267 + 7 beats/min and 259 + 19 - -
-6 5 
beats/min, methoxamine 10 Mand 10- M values 250 + 6 beats/min and 
290 + 11 beats/min respectively. (p non significant) 
3-2 
(b) coronary flow rates control values 8.3 ± 0.5 ml/min and 7.2 + 
-6 -5 
0.7 ml/min, methoxamine 10 Mand 10 M values 8.5 ± 0.7 ml/min and 
9.5 + 0.8 ml/min respectively. (p non significant). (Table 1) 
(c) metabolic status 
(i) adenosine triphosphate, control value 3.8 ± 0.2 pmol/g, 
-6 -5 
methoxamine 10 Mand 10 M values 3.7 ± 0.4 pmol/g and 3.6 + 
0.2 pmol/g respectively. 
(ii) lactate, control value 3.1 ± 0.4 pmol/g, methoxamine l0-
6M and 
-5 10 M values 2.8 ± 0.1 pmol/g and 3.6 ± 0.8 pmol/g 
respectively. 
(iii) cyclic adenosine monophosphate, control value 0.44 + 0.02 
nmol/g, methoxamine l0-
6M value 0.43 + 0.03 nmol/g (p non 
significant) (Table 2). 
The QT interval remained ~nchanged with methoxamine l0-
7M but increased 
with higher concentrations, control values 79.6 + 3.1 msec and 81.0 + 
-6 -5 
3.8 msec, methoxamine 10 Mand 10 M values 94.6 ± 4.4 msec (p ( 0.01) 
and 97.3 + 4.7 msec (p ( 0.01) respectively (Table 1) • 
Alpha
1
-adrenoceptor stimulation with methoxamine l0-
6M and l0-
5M also 
produced a positive inotropic effect (Figure 2). 
-5 
Methoxamine 10 M 
increased the left ventricular systolic pressure from a control value of 
80.8 ± 3.1 mmHg to 113.4 ± 2.5 mmHg. A characteristic three-phasic time 
course to the positive inotropic effect was evident. An initial small 
increase in left ventricular systolic pressure was noted after thirty 
seconds of adding methoxamine, this was followed by a second phase where 
the left ventricular systolic pressure plateau's or decreases 
momentarily before increasing slowly to a maximum effect at four minutes 
(Figure 2) . No change in left ventricular end diastolic pressure was 
evident (results not shown). Accompanying the positive inotropic effect 
3-3 
was an increase in oxygen demand, control values 108.6 ~ 9.7 pml/g/min 
-6 -5 
and 125.0 ! 8.3 pml/g/min, methoxamine 10 M and 10 M values 165.6 + 
8.1 pml/g/min (p ( 0.01) and 190.0 + 14.5 fml/g/min (p ( 0.01) 




-adrenoceptor stimulation in the normoxic ventricular 
myocardium 
B-HT 920 and the more selective agent B-HT 933 are reputed to act 
selectively on the alpha2-a
drenoceptor (Van Zwieten and Timmermans, 
1983. Kobinger and Pichler, 1980). The log concentration response 
curves of both B-HT 920 and B-HT 933 demonstrate no alteration in 
ventricular fibrillation threshold (figures 3 and 4). No positive 
inotropic effect was evident with B-HT 933 (Figures 5). No 
alteration in heart rate or coronary flow rate occurred with the 
addition of alpha2
-agonists (Tables 3 and 4). 
Alpha1
-adrenoceptor antagonism with prazosin 
-8 
Prazosin 10 M produces a tenfold displacement to the right of the 
log concentration response curve of the positive inotropic effect 
of methoxamine (Figure 6) indicating specific alpha1
-adrenoceptor 
-8 
antagonism. Prazosin 10 M prevents the enhanced vulnerability to 
-6 
ventricular fibrillation induced by methoxamine 10 M (Figure 7). 
The ventricular antiarrhythmic effect of prazosin was not 
accompanied by alteration in the following, 
(a) heart rate, 243 + 15 beats/min versus 256 + 15 beats/min. 
(b) coronary flow rates, 6.0 + 6 ml/min versus 7.2 + 0.4 ml/min 
(c) metabolic status 
(i) adenosine triphosphate, 3.9 + 0.1 pmol/g versus 3.8 + 
0.2 pmol/g. 
3-4 
(ii) lactate, 3.4 ~ 0.1 pmol/g versus 3.1 + 0.4 pmol/g. 
(iii) cyclic adenosine monophosphate, 0.47 ~ 0.02 nmol/g versus 





The findings presented in this study provide evidence that 
alpha
1
-adrenoceptor stimulation is arrhythmogenic in the normoxic 
rat ventricular myocardium. This proposal is based on the 
following evidence. Firstly, specific alpha1
-adrenoceptor 
stimulation with methoxamine increases the vulnerability to 
ventricular fibrillation. This was accompanied by an increase in 
QT interval, an indirect index of an increase in action potential 
duration (a well described electrophysiological effect of 
alpha
1
-adrenoceptor stimulation). Secondly alpha2
-adrenoceptor 
stimulation with B-HT 920 and B-HT 933 does not alter vulnerability 
to ventricular fibrillation. Thirdly the arrhythmogenic effect of 
methoxamine is not due to beta-adrenoceptor stimulation as the 
experiments were conducted in the presence of the selective 
beta-adrenoceptor antagonist agent atenolol. Furthermore there was 
no attendant evidence of beta-adrenoceptor stimulation as manifest 
by (i) no increase in myocardial cyclic AMP content and (ii) no 
positive chronotropic effect. Fourthly, the selective 
alpha1
-adrenoceptor antagonist agent prazosin l0-
8
M (Kobinger and 
Pichler, 1980. Van Zwieten and Timmermans, 1983. Exton 1983) 
prevents the arrhythmogenic action of methoxamine. Selective 
alpha1
-adrenoceptor antagonism is evident by the finding that 
prazosin produces a tenfold displacement to the right of the log 
concentration response curve of th'e positive inotropic effect of 
methoxamine (Figure 6). 
3-5 
Prazosin also prevents spontaneous ventricular arrhythmias during 
acute regional myocardial ischaemia in the feline model (Sheridan 
et al ., 1980). Fifthly, the arrhythmogenic action of methoxamine was 
unassociated with reduction in the coronary flow rate. 
Alpha-adrenoceptor stimulation may cause coronary vasoconstriction. The 
increase in metabolic rate secondary to the concomitant positive 
inotropic effect of methoxamine presumably accounts for the absence of 
changes in coronary perfusion rate. Sheridan and co-workers have 
demonstrated that the ventricular antiarrhythmic action of prazosin 
during acute regional myocardial ischaemia (and subsequent reperfusion 
of the ischaemic myocardium) cannot be ascribed to alteration in 
regional myocardial perfusion rate as measured by the miscrosphere 
method. (Sheridan et al., 1980). 
-6 -5 
Finally, methoxamine 10 M to 10 M 
did not produce metabolic evidence of myocardial high energy phosphate 
depletion or accumulation. of myocardial lactate, an index of anaerobic 
metabolism. The ability of prazosin to reverse the methoxamine induced 
fall in ventricular fibrillation threshold occurred independent of 
preservation of myocardial high energy phosphate stores or reduction in 
normal myocardial lactate content. Prazosin did not inhibit the 
methoxamine induced increase in QT interval, hence the arrhythmogenic 
action of methoxamine cannot be attributed to prolongation of the action 
potential duration. 
The arrhythmogenic action of methoxamine was accompanied by an increase 
in left ventricular systolic pressure generation whilst relaxation was 
unaffected. The positive inotropic effect elicited by methoxamine can 
be attributed to pure alpha-adrenoceptor stimulation since (i) it 
occurred in the presence of the beta-adrenoceptor antagonist agent 
3-6 
atenolol and (ii) it was unassociated with an increase in myocardial 
cyclic adenosine monophosphate concentration. The positive inotropic 
effect of alpha-adrenoceptor stimulation differs from that evident with 
beta-adrenoceptor stimulation as evident from the following : firstly, 
time to peak left ventricular systolic pressure generation occurs after 
four minutes with alpha-adrenoceptor stimulation whereas with 
beta-adrenoceptor stimulation it occurs within 15 to 30 seconds. 
beta-adrenoceptor stimulation activates the relaxation Secondly 














stimulation produces a chronotropic 
Methoxamine increases the slow calcium inward current and may 
potentially evoke the re:lease of · calcium from intracellular stores . 
Exton and co-workers have shown an increase in cytosolic calcium 
occurring within seconds of alpha1
-adrenoceptor stimulation in rat 
liver cells (Exton, 1981). A calcium ion mediated process may 
therefore be responsible for mediating (i) the arrhythmogenic 
action and (ii) the positive inotropic effect of 
alpha1
-adrenoceptor stimulation with methoxamine. This potential 
role of calcium in the arrhythmogenic action of methoxamine is 




The log concentration response curves of B-HT 920 and B-HT 933 
(azepexole) show that alpha2
-adrenoceptor stimulation does not 
increase vulnerability to ventricular fibrillation in the normoxic 
3-7 
rat ventricular myocardium (Figures 3 and 4). No alteration in 
(i) left ventricular systolic pressure generation 
(ii) oxygen demand 
(iii) metabolic status or 
(iv) coronary flow rate 





the presence of 
alpha2
-adrenoceptors in rat ventricular myocardium and argue 
against a functional role for alpha2
-adrenoceptors in rat 
ventricular myocardium. Moreover indirect support is provided for 





-adreqoceptor stimulation with methoxamine increases 
vulnerability to ventricular fibrillation · in the normoxic rat 
ventricular myocardium ; alpha2-ad
renoceptor stimulation is without 
effect. 
2) The arrhythmogenic action of methoxamine occurs in the setting of 
beta-adrenoceptor antagonism and is not associated with myocardial 
accumulation of cyclic AMP (the proposed arrhythmogenic 
intracellular second messenger of beta-adrenoceptor stimulation). 
No alteration in heart rate or coronary flow rate occurred. 
3) No depletion of myocardial high energy phosphate stores accompanied 
the arrhythmogenic action of methoxamine. 
4) The arrhythmogenic action of methoxamine is associated with a 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































THE POSSIBLE ROLE OF TRANSSARCOLEMMAL CALCIUM MOVEMENT AND SARCOPLASMIC 




A) Transsarcolemmal calcium ion movement 
1) 
The possible role of transsarcolemmal calcium movement in 
alpha1 
-adrenoceptor mediated responses was explored by two 






the methoxamine .10 M induced fall in ventricular fibrillation 
threshold, (Figure 8) and 
(ii) the positive inotropic effect of 
-6 -5 
methoxamine 10 M to 10 M 
(Figure 9). 
The ventricular antiarrhythmic effect was associated with 
(a) an increase in coronary flow rate, 14.3 + 0.6 ml/min versus 9 . 8 
±" 0.8 ml/min (p ( 0.01) and 
(b) inhibition of the increase in QT interval; control to 
-6 
methoxamine 10 M values 79.6 + 3.1 msec to 94.6 + 4.4 msec (p < 
-6 
0.01) respectively; control to methoxamine 10 M plus 
nisoldipine 10-
8M values, 76.0 + 4 . 7 msec to 88.7 + 2.2 msec (p 
= 0 . 06) respectively (Table 5) . 
4-2 
There was no alteration in the fo l lowing: 
(i) Heart rate 244 + 14 beats/min versus 280 + 23 beats/min (p 
non significant) 
(ii) Metabolic status 
2) 
Adenosine triphosphate 4.1 + 0.1 pmol/g versus 3.8 + 0.2 
fmol/g (p non significant). 
lactate 3 . 3 + 0.5 pmol/g versus 3 . 1 + 0.4 pmol/g (p non 
significant) 
cyclic adenosine monophosphate 0 . 42 ~ 0 . 02 nmol/g versus 
0.44 + 0.02 nmol/g. (p non significant).(Tables 5 and 6). 
Lowering extracellular calcium inhibits the methoxamine induced 
-6 
fall in ventricular fib r illation threshold: methoxamine 10 M plus 
calcium 2.5 mM value 4 . 1 + 1;2 mA, methoxamine l0-
6M plus calcium 
. -
1.25 mM value 14 . 1 + 2. 5 mA (p ( 0.01) (Figure 8). 
The protective effect of lowering extracellular calcium was 
unassociated with alteration in the following: 
(i) coronary flow rate, 11 . 8 + 0.6 ml/min versus 11.3 + 0 . 3 ml/min 
or 
(ii) heart r a te 266 + 7 beats/min versus 280 + 12 beats/min. (p 
non signif i cant) 
Reducing ex tracellular calcium inhibits the methoxamine l0-
6M 
induced increase in 
(i) left ventricular systolic pressure , 85.3 + 3. 5 mmHg versus 
113.4 ~ 2.5 nunHg (Figure 9) and 
(ii) oxygen demand, 140 . 5 + 9.4 pml/g/min versus 165.6 + 8.1 
pml/g/min (Tables 5 and 6) . 
B) 
4-3 
Sarcoplasmic reticulum calcium release 
The possible role of sarcoplasmic reticulum calcium ion release in 
alpha1-ad
renoceptor mediated responses was explored using 
ryanodine. Ryanodine l0-
9M inhibits the methoxamine induced fall 
in ventricular fibrillation threshold: 
-6 
methoxamine 10 M value 4.1 
+ -6 -9 - 1.2 mA, methoxamine 10 M plus ryanodine 10 M value, 14.2 ±2.4 
mA (Figure 10). 
-9 8 
Ryanodine 10 M and 10- M inhibits the positive 
inotropic effect of methoxamine l0-
6M and 10-SM respectively 
(Figure 11, Table 7). The protective effect of ryanodine could not 





coronary flow rate 10.9 + 0.4 ml/min versus 11.0 + 0.3 
ml/min (p non significant). 
heart rate 268 + 11 be·ats/min versus 268 + 15 beats/min (p 
non significant). 
-9 
QT interval Ryanodine 10 M does not prevent the increase in 
QT interval; 
-6 + 
control to methoxamine 10 M values 79.6 - 3 . 1 
msec to 94 . 6 ~ 4.4 msec (p( 0.01) respectively; control to 
-6 -9 
methoxamine 10 M plus ryanodine 10 M values 78.7 + 3.4 
rnsec to 94.7 + 2.0 rnsec (p(0.01) respectively. 
metabolic status - adenosine triphosphate, 4.3 + 0.1 rmol/g 
versus 3.8 ~ 0.2 µmol/g. 
- lactate, 2.9 ~ 0.1 pmol/g versus 3 .1 + 






-adrenoceptor stimulation increases transsarcolemmal calcium ion 
influx by phosphorylation of a 15000 MW sarcolemmal protein in the rat 
heart (Lindemann and Wilson, 1984). It may also induce the release of 
calcium from the sarcoplasmic reticulum in rat liver (Exton, 1981). 
Enhanced transsarcolemmal calcium influx or sarcoplasmic reticulum 
calcium release may result in an increase in intracellular free calcium 
ion concentration (Figure 12). Increased transsarcolemmal calcium 
influx may induce slow response action potentials (Reuter, 1974) whereas 
enhanced sarcoplasmic reticulum calcium release may evoke depolarizing 
after potentials (Reuter, 1974). Each of these electrophysiological 
alterations are considered to predispose to ventricular fibrillation. 
The arrhythmogenic effect.of methoxamine was associated with a positive 
inotropic effect (compare figures 1 and 2). An increase in force of 
contraction is ultimately due to an increase in cytosolic calcium ion 
concentration or increase in sensitivity of myofilaments to calcium or 
both. Hence it is possible that the arrhythmogenic action of 
alpha
1
-adrenoceptor stimulation was associated with an increase in 
cytosolic calcium. 
The possible role of transsarcolemmal calcium ion influx was explored by 
use of (1) nisoldipine and (2) lowering extracellular calcium ion 
concentration. Nisoldipine, a dihydropyridine derivative inhibits the 
voltage dependent influx of calcium (Henry et al . , 1980). Nisoldipine 
binds with the nitrendipine binding site in cardiac sarcolemma (Murphy 
and Snyder, 1982), reputedly at the calcium channel or a site 
4-5 
functionally related to this channel (Sarmiento et al., 1983). It is 
relatively selective since it does not bind with the sodium cha
nnel 
(Henry et al., 1980), has no affinity for the alpha1
-adrenoceptor 
(Motulsky et al., 1983) and leaves the outward potassium cur
rent 
unaltered (Kass 1982). Decreasing the extracellular calcium 
ion 
concentration reduces the driving force for calcium since calcium 
ions 
are considered to depolarize the cell membrane. 
Both nisoldipine and low extracellular calcium ion concentra
tion 
prevented the methoxamine induced fall in ventricular fibrillat
ion 
thresho ld. The protective effect afforded by nisoldipine was associ
ated 
with an increase in myocardial perfusion rate. It is unlikely that
 the 
ventricular antiarrhythmic effect of nisoldipine was due to 
an 
improvement in myocardial perfusion as 
(1) the arrhythmogenic a~d positive inotropic effect of methoxamine
 was 
not accompanied by a decrease in myocardial perfusion rate. 
(2) lowering extracellular calcium concentration inhibited the 
arrhythmogenic and positive inotropic effect of methoxamine without 
improvement in myocardial perfusion rate. 
(3) the protective effect of prazosin was not associated with an 
increase in myocardial perfusion rate. 
The protective effect of nisoldipine and lowered extracellular calc
ium 
ion concentration could not be ascribed to alteration in QT inter
val, 
reduction in heart rate or improvement in myocardial metabolic statu
s. 
Ryanodine was used to explore the possible role of sarcoplas
mic 
reticulum calcium ion release in the genesis of ventricula
r 
fibrillation induced by alpha1
-adrenoceptor stimulation. 
4-6 
Ryanodine is considered to inhibit the phasic release of calcium
 ions 
from the sarcoplasmic reticulum but doe s not alter the transsarcol
emmal 
calcium ion influx. Evidence for this proposal is as follows: 
(1) the negative inotropic response to ryanodine . in ventricular 
myocardium correlates with the species dependence on sarcoplasmic 
reticulum calcium release for contractile development (Sutko and 
Willerson, 1980). 
(2) ryanodine prevents the contractile response to paired electri
cal 
stimulation which is thought to be mediated by enhanced 
sarcoplasmic reticulum calcium r e lease (Sutko et al., 1979. Sutko
 
and Willerson, 1980). 
(3) ryanodine a llows the treppe effect (positive inotropy in resp
onse 
to increase in heart rate) but inhibits the post rest contractile 
response (considered to be dependent on sarcoplasmic reticulum 
calcium ion release)~ (Frank and Sleator, 1975. Sutko and 
Willerson, 1980). 
(4) ryanodine abolishes the aequorin signals evoked by calcium 
induced calcium release in skinned ventricular myocytes (A. Fabiat
o 
in Sutko and Kenyon, 1983). 
(S) ryanodine abolishes after contractions and prevents 
afterpotentials, electrophysiological alterations presumed to 
result from oscillatory release of calcium from the sarcoplasmic 
reticulum (Sutko and Kenyon, 1983). 
(6) ryanodine may potentiate calcium uptake in isolated cardiac 
sarcoplasmic reticulum preparations (Jones et al . , 1979). 
(7) ryanodine l0-
6M does not inhibit the slow inward calcium current 
(Sutko and Kenyon, 1983). 
4-7 
(8) according to two calcium dependent processes, phosphorylase 
A 
activity and resting tension, ryanodine decreases intracell calci
um 
activity in rat ventricular myocardium (Sutko and Kenyon, 1983). 
Ryanodine prevented the arrhythmogenic effect of methoxamine
. This 
protective effect could not be ascribed to alteration in QT in
terval, 
reduction in heart rate, improvement in coronary flow r
ate or 
preservation of metabolic status. 
In this isolated rat heart preparation nisoldipine, re
duced 
extracellular calcium, and ryanodine each prevented the arrhyth
mogenic 
action of methoxamine. All three procedures may have a common end
 effect 
of reducing intracellular free calcium ion concentration. Co
nsistent 
with this hypothesis was the finding that all three procedures p
revented 
the methoxamine induced increase in left ventricular systolic pr
essure . 
Thus reduction in intracellular free calcium ion concentration
 may be 
the possible mechanism underlying . the antiarrhythmic activity
. This 
suggests that calcium ion influx across the sarcolemma or the
 phasic 
release of calcium ions from the sarcoplasmic reticulum may 
play an 




Indirect support for the above hypothesis stems from the findings
 of: 
1 . Exton and co-workers who demonstrated an increase in cytosolic 
calcium occurring within one second of alpha1
-adrenoceptor 
stimulation in rat liver cells (Exton 1981). 
2. Corr and co-workers, who showed enhanced alpha1
-adrenoceptor 
responsiveness upon reperfusion of the acutely ischaemic 
cat 
myocardium (Corr et al . , 1981). 
4-8 
3. Sharma and co-workers, who reported that alpha1
-antagonist agents 
(prazosin amongst others) prevent the accumulation of intracellula
r 
calcium 10 minutes after reperfusion of the acutely ischaemic cat 
myocardium (Sharma et al., 1983). 
CONCLUSIONS 
Alpha1
-adrenoceptor stimulation enhances the. vulnerability to 
ventricular fibrillation in the isolated perfused rat heart. 
This 
sequence is inhibited by procedures thought to decrease cytosolic 
calcium concentration. The possible mechanism und
erlying 
alpha1
-adrenoceptor mediated responses may be an increase in cytosolic
 
calcium ion concentration secondary to either 
(i) an enhanced transsarcolemmal calcium ion influx or 
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Ryanodi ne 10-9M 
Influence of ryanodine 10-9M on the methoxamine 
10-6M induced positive inotropic effect 
Left ventricular systolic pressure 
(mmRg) 
0 minutes 4 minutes 
76.3 :t 1.2 75.7 :t 1.2 
79.0 ± 2.8 p<0.05 95.4 :t 6.0 
75.4 :t 0.7 p-NS 81.2 ± 4.3 
Results expressed as mean± SEM 
Number of experiments= 5-6 in each series 
All experiments undertaken with atenolol 10-6M 






-adrenoceptor stimulation with methoxamine enhanced the 
vulnerability to ventricular fibrillation in the normoxic rat 
ventricular myocardium; alpha2
-adrenoceptor stimulation with B-HT 
920 and B-HT 933 was without effect. 
2) The arrythmogenic action of methoxamine was accompanied by the 
following: 
(a) an increase in QT interval (an indirect index of prolongation of 
the action potential duration). 
(b) an increase in oxygen demand and 
(c) a positive inotropic effect with a characteristic triphasic 
response. 
3) The alpha 1
-adrenoceptor mediated responses occurred in the presence 
of the beta-adrenoceptor antagonist agent atenolol, and were not 
associated with an increase in myocardial cyclic AMP concentration. 
There was no alteration in heart rate, coronary flow rate or 
metabolic status. 
4) Specific alpha1
-adrenoceptor antagonism with prazosin prevented both 
the enhanced vulnerability to ventricular fibrillation and the 
positive inotropic effect of methoxamine. 
5) Nisoldipine and reduced extracellular calcium, procedures considered 
to inhibit transsarcolemmal calcium ion influx, prevented the 
arrhythmogenic and positive inotropic effect of methoxamine . 
5-2 
Ryanodine, an agent which is reputed to inhibit sarcoplasmic 
reticulum calcium ion release, also prevented the arrhythmogenic and 
positive inotropic effect of methoxamine . These interventions are 
considered to have a common end effect in reducing intracellular 
calcium ion concentration. 
6) The possible mechanism underlying the arrhythmogenic action of 
alpha1
-adrenoceptor stimulation might therefore be an increase in 
cytosolic calcium ion concentration. This increase in cytosolic 
calcium ion concentration may be secondary to an enhanced 
transsarcolemmal calcium ion influx or an increase in the phasic 
release of calcium ions from the sarcoplasmic reticulum. 
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